Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 152,831 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Presessions for the National Diabetes Prevention Program

NCT04022499
View directory record Official record
Conditions
Prediabetic State, Obesity, Gestational Diabetes
Interventions
Presessions, National Diabetes Prevention Program
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00003299
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
QGE031, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 25, 2026, 4:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool

NCT00987298
View directory record Official record
Conditions
Obesity
Interventions
Visceral fat mass measurement
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 90 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 25, 2026, 4:32 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders

NCT01867398
View directory record Official record
Conditions
Conduct Disorder, fMRI
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 25, 2026, 4:32 AM EDT
Recruiting Phase 2 Interventional

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Jacksonville, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Interventions
onaBoNT-A + placebo, Tamsulosin + placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 25, 2026, 4:32 AM EDT
Not listed Not applicable Interventional

Green Light Effects on Anxiety

NCT04871087
View directory record Official record
Conditions
Anxiety
Interventions
Green Light
Device
Lead sponsor
The Green Light Study Center
Other
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Not applicable Interventional

EMA of Substance Use in Homeless Youth

NCT04884087
View directory record Official record
Conditions
Substance Use
Interventions
Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day, Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day, Incentive Structure - fixed, Incentive Structure - prize based
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Years to 24 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 25, 2026, 4:32 AM EDT
Completed No phase listed Observational

Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor in Children With Asthma

NCT02866487
View directory record Official record
Conditions
Asthma
Interventions
Bronchoscopy
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
Up to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Using m-Health Tools to Reduce the Misuse of Opioid Pain Relievers

NCT03012087
View directory record Official record
Conditions
Prescription Drug Abuse
Interventions
MyHealthyChoices, Health Risk Assessment
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

NCT04537793
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT00096993
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Placebo, Gemcitabine, Pertuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 25, 2026, 4:32 AM EDT
Completed No phase listed Observational

Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States

NCT06178393
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 5 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 25, 2026, 4:32 AM EDT
Completed No phase listed Observational

Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions

NCT01609621
View directory record Official record
Conditions
Peripheral Arterial Disease, Critical Limb Ischemia
Interventions
Retrograde tibiopedal arterial access
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
Not listed
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

NCT00257621
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW640385, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 4:32 AM EDT
Enrolling by invitation Not applicable Interventional

Cognitive Effects of Exercise in Parkinson's Disease

NCT06823921
View directory record Official record
Conditions
Parkinson Disease
Interventions
Exercise
Other
Lead sponsor
Sule Tinaz
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 25, 2026, 4:32 AM EDT
Enrolling by invitation No phase listed Observational

The Effect of Ablation Therapy on Barrett's Esophagus

NCT00587314
View directory record Official record
Conditions
Barrett's Esophagus, Early Esophageal Adenocarcinoma
Interventions
Biopsy
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

NCT01056614
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Hematopoietic/Lymphoid Cancer, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
fludarabine phosphate, busulfan, anti-thymocyte globulin, tacrolimus, methotrexate, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 25, 2026, 4:32 AM EDT
Withdrawn Phase 4 Interventional

Comparing Diuretic Strategies in Hospitalized Heart Failure

NCT03999216
View directory record Official record
Conditions
Heart Failure
Interventions
Loop Diuretics vs. loop + thiazide diuretics
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 25, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

NCT00865904
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 25, 2026, 4:32 AM EDT
Not listed Not applicable Interventional

Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial

NCT02258984
View directory record Official record
Conditions
Severe Sepsis, Acute Heart Failure
Interventions
Mespere Venus 1000 Non-Invasive CVP System
Device
Lead sponsor
Mespere Lifesciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 25, 2026, 4:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The College, Alcohol and Peers Study (CAPS)

NCT03890484
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Peer Type - New Peer, Peer Type - Close Friends
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 25, 2026, 4:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Database Surveillance Safety Study of PENTACEL® Vaccine

NCT00804284
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae
Interventions
DTaP-IPV/Hib, Other DTap Vaccines
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Weeks to 24 Months · Male only
Enrollment
62,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 25, 2026, 4:32 AM EDT